Hikal (NSE:HIKAL) Beneish M-Score: -3.01 (As of Jul. 02, 2026)


NSE:HIKAL Hikal Ltd NSE:HIKAL
67 GF Score
Price ₹218.96
GF Value ₹275.89
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Hikal Beneish M-Score?

Hikal NSE:HIKAL -1.09% 67 Beneish M-Score is -3.01 as of Jul. 02, 2026. GuruFocus rates NSE:HIKAL with a GF Score™ of 67/100 and a GF Value™ of ₹275.89 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 908 Drug Manufacturers companies, Hikal ranks better than 83.26% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -3.01 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Hikal's Beneish M-Score or its related term are showing as below:

NSE:HIKAL' s Beneish M-Score Range Over the Past 10 Years
Min: -3.01   Med: -2.77   Max: -2.38
Current: -3.01

During the past 13 years, the highest Beneish M-Score of Hikal was -2.38. The lowest was -3.01. And the median was -2.77.


Hikal Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Hikal's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hikal Beneish M-Score Chart

Hikal Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.91 -2.90 -2.76 -2.82 -3.01

Hikal Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.82 0.00 0.00 0.00 -3.01

NSE:HIKAL vs ZTS, UTHR: Beneish M-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Hikal's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hikal Beneish M-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hikal's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Hikal's Beneish M-Score falls into.


NSE:HIKAL
67GF Score
Hikal Ltd NSE:HIKAL
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hikal Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Hikal for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.9171+0.528 * 0.9912+0.404 * 1.3846+0.892 * 0.9196+0.115 * 0.8021
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0+4.679 * -0.148305-0.327 * 0.9728
=-3.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was ₹4,419 Mil.
Revenue was ₹16,952 Mil.
Gross Profit was ₹9,335 Mil.
Total Current Assets was ₹8,841 Mil.
Total Assets was ₹23,654 Mil.
Property, Plant and Equipment(Net PPE) was ₹14,216 Mil.
Depreciation, Depletion and Amortization(DDA) was ₹1,638 Mil.
Selling, General, & Admin. Expense(SGA) was ₹0 Mil.
Total Current Liabilities was ₹6,789 Mil.
Long-Term Debt & Capital Lease Obligation was ₹3,758 Mil.
Net Income was ₹-488 Mil.
Gross Profit was ₹0 Mil.
Cash Flow from Operations was ₹3,020 Mil.
Total Receivables was ₹5,240 Mil.
Revenue was ₹18,435 Mil.
Gross Profit was ₹10,062 Mil.
Total Current Assets was ₹9,954 Mil.
Total Assets was ₹25,289 Mil.
Property, Plant and Equipment(Net PPE) was ₹14,874 Mil.
Depreciation, Depletion and Amortization(DDA) was ₹1,344 Mil.
Selling, General, & Admin. Expense(SGA) was ₹852 Mil.
Total Current Liabilities was ₹7,895 Mil.
Long-Term Debt & Capital Lease Obligation was ₹3,696 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(4419 / 16952) / (5240 / 18435)
=0.260677 / 0.284242
=0.9171

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(10062 / 18435) / (9335 / 16952)
=0.54581 / 0.550672
=0.9912

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (8841 + 14216) / 23654) / (1 - (9954 + 14874) / 25289)
=0.025239 / 0.018229
=1.3846

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=16952 / 18435
=0.9196

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(1344 / (1344 + 14874)) / (1638 / (1638 + 14216))
=0.082871 / 0.103318
=0.8021

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(0 / 16952) / (852 / 18435)
=0 / 0.046216
=0

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((3758 + 6789) / 23654) / ((3696 + 7895) / 25289)
=0.445887 / 0.458342
=0.9728

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-488 - 0 - 3020) / 23654
=-0.148305

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Hikal has a M-score of -3.01 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -3.01 mean?
Hikal (NSE:HIKAL) has a Beneish M-Score of -3.01 as of Jul. 02, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Hikal and its competitors. According to the industry distribution chart, Hikal ranks #152 out of 908 companies in the Drug Manufacturers industry, placing it in the top 16.7%.
Is Hikal's Beneish M-Score too high?
Hikal's current Beneish M-Score is -3.01. Based on the distribution chart, Hikal ranks #152 out of 908 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Hikal has a GF Score™ of 67/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Hikal's Beneish M-Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Hikal ranks #152 out of 908 companies for Beneish M-Score. This places Hikal in the top 17% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Drug Manufacturers company?
A good Beneish M-Score depends on the Drug Manufacturers industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Hikal and its competitors. Hikal's current Beneish M-Score is -3.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hikal stock overvalued right now?
Based on GuruFocus' analysis, Hikal (NSE:HIKAL) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹275.89, compared to a current price of ₹218.96 — trading 20.6% below its estimated fair value. The current Beneish M-Score is -3.01. Hikal's overall GF Score™ is 67/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Hikal (NSE:HIKAL), the current Beneish M-Score is -3.01 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hikal (NSE:HIKAL) Overvalued in 2026?

Based on GuruFocus' analysis, Hikal stock appears to be undervalued. The current stock price of ₹218.96 is trading 20.6% below its estimated GF Value™ of ₹275.89. GuruFocus considers Hikal to be Modestly Undervalued.

Key valuation signals for NSE:HIKAL:

  • Beneish M-Score: -3.01
  • GF Value™: ₹275.89 vs. price of ₹218.96 (20.6% below fair value)
  • GF Score™: 67/100 with 5 warning signs

No single metric tells the full story. See the NSE:HIKAL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Hikal Business Description

Other Exchanges 524735:India
Address Great Eastern Chambers, 6th Floor, Sector 11, CBD Belapur, Navi Mumbai, MH, IND, 400 614
Hikal Ltd manufactures chemical intermediates, specialty chemicals, active pharmaceutical ingredients, and contract research activities. Its products are distributed to the pharmaceutical, biotech, agrochemical, and specialty chemical industries. Its segments include Crop Protection and Pharmaceuticals. The majority of the revenue is derived from the pharmaceutical segment.
67GF Score

Get the complete analysis for NSE:HIKAL

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹218.96
Price
₹275.89
GF Value